Clinical prognostic risk analysis and progression factor exploration of primary breast lymphoma

Figures & data

Table 1. Clinical charactar of all 63 female PB-DLBCL.

Characteristic	Overall, N = 63^0
Age	52 (46, 61)
Year
2003–2010	21(33%)
2010–2020	42(67%)
Postmenopausal	36(57%)
Sugery
None	34 (54%)
Lumpectomy	15 (24%)
Modified radical mastectomy/mastectomy	14 (22%)
Site
Left	28 (44.5%)
right	31 (49.2%)
bilateral	4 (6.3%)
Bulky disease > 5cm^1	12(20%)
COO^2
GCB	14(22.3%)
non-GCB	37 (58.7%)
NA	12(19%)
DEL^3
Yes	13 (20.6%)
No	18(28.6%)
NA	32(50.8%)
Ki_67^4	80% (70%, 90%)
Stage
I	25 (40%)
II	34 (54%)
IV	4 (6%)
IPI
0	33(52%)
1	20(32%)
2	5(8%)
3	5(8%)
B_symptom	9 (14.3%)
Elevated ESR	20 (32%)
Elevated β2_MG	4 (6.3%)
Elevated LDH	15 (23.8%)

0.Median (IQR); n (%);1.61 had statistic; 2. 51 had complete IHC-COO(HANS marker); 3.31 had complete cmyc/bcl2/bcl6 expression; 4. 54 had ki-67 statistics. NA, not acquired.

Figure 1. Kaplan-Meier curve of PB-DLBCL patients, a. OS, b. PFS.

Figure 2. Kaplan-Meier curve of OS and PFS on Stage and COO a-b. Stage of OS and PFS, c. COO of OS.

Figure 3. a-d,Kaplan-Meier curve of B symptom, ESR, LDH, and IPI in PFS, e. IPI and stage adjusted-IPI of OS.

Figure 4. Kaplan-Meier curve of OS and PFS depend on Rituximab use.

Figure 5. Kaplan-Meier curve of OS on CNS relapse and ASCT a. CNS relapse, b. CNS relapse, non-CNS relapse and non relapse, c. ASCT in R/R patients.

Table 2. Summarize of 25 relapse/progression patients.

Recurrence	N = 25^1	n = 28^1
Contralateral breast	6 (24%)	6
Local breast	5 (20%)	7
Skin/soft tissue	5 (20%)	5
CNS^2	3 (12%)	6
CNS + Local breast	2(8%)	-
Adnexa uteri	1 (4%)	1
Kidney	1 (4%)	1
Lymph node	1 (4%)	1
Pancreas	1 (4%)	1

1. N, number of relapsed patients, n, number of relapsed site

2. 1 patient developed CNS progression 2 months after contralateral breast progression.

Table 3. Univariate and multivariate analysis of OS and PFS.

	OS							PFS
		Univariate			Multivariate			Univariate			Multivariate
	Characteristics	HR	CI95%	p				HR	CI95%	p
1	bilateral	28.35	4.67-172.19	<0.001	2.24	0.17-29.95	0.543	51.66	9.02-295.82	<0.001	23.54	2.5-221.47	0.006
2	Bulky > 5cm	2.51	0.77-8.19	0.128	-			2.13	0.82-5.54	0.12	-
3	COO	2.71	0.34-21.37	0.345	-			1.25	0.41-3.79	0.691	-
4	B symptom	7.53	2.37-23.91	0.001	6.89	1.54-30.85	0.012	3.97	1.54-10.22	0.004	2.6	0.91-7.41	0.074
5	ESR	9.79	2.7-35.41	0.001	6	1.17-30.88	0.032	3.82	1.65-8.85	0.002	2.03	0.67-6.18	0.211
6	LDH	6.18	2.09-18.28	0.001	0.86	0.17-4.2	0.849	4.52	1.94-10.49	<0.001	2.26	0.62-8.16	0.215
7	Rituximab	0.48	0.16-1.39	0.176	-			0.6	0.26-1.38	0.226	-
8	CNS prophylaxis	0.5	0.17-1.52	0.223	-			0.75	0.3-1.92	0.553	-	36,39
9	radiotherapy	1.36	0.42-4.4	0.609	-			0.57	0.19-1.7	0.315	-
10	Relapse/recurrent	4.07	1.27-13.03	0.018	1.98	0.43-9.21	0.382	-			-
11	CNS relapse	4.34	1.34-14.04	0.014	2.56	0.55-11.89	0.232	-			-
12	IPI 2–3	7.94	2.44-25.85	0.001	4.86	0.53-40.64	0.167	4.1	1.56-10.8	0.004	0.64	0.11-3.54	0.605